Four patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2034. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2034
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2018 to 2035.
US 9,962,534
Microarray for Delivery of Therapeutic Agent, Methods of Use, and Methods of Making
Mar 28, 2035
20222026203020342035
1 pending application: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2034 · High confidence
Also notable
Ends Oct 2034 · High confidence
Also notable
Ends Mar 2035 · High confidence
Microarray for Delivery of Therapeutic Agent and Methods of Use
US 11,052,231
The most cited patent in this portfolio, cited by 28 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2034.
Microarray for Delivery of Therapeutic Agent and Methods of Use
US 10,384,046
Cited by 27 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2034.
Microarray for Delivery of Therapeutic Agent, Methods of Use, and Methods of Making
US 9,962,534
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Microarray for Delivery of Therapeutic Agent and Methods of Use (US 10,384,046) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 1 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Microarray for Delivery of Therapeutic Agent and Methods of Use | 2 in force | to Oct 2034 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,565,097 | Microarray for Delivery of Therapeutic Agent and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 10,384,046 | Microarray for Delivery of Therapeutic Agent and Methods of Use In force · High confidence | In force | High confidence | |
| US 11,052,231 | Microarray for Delivery of Therapeutic Agent and Methods of Use In force · High confidence | In force | High confidence | |
| US 9,962,534 | Microarray for Delivery of Therapeutic Agent, Methods of Use, and Methods of Making In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 1 application pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.